"Kallikreins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC 3.4.21.34), TISSUE KALLIKREIN (EC 3.4.21.35), and PROSTATE-SPECIFIC ANTIGEN (EC 3.4.21.77).
| Descriptor ID |
D007610
|
| MeSH Number(s) |
D08.811.277.656.300.760.442 D08.811.277.656.959.350.442 D12.776.124.125.597 D23.119.597
|
| Concept/Terms |
Kallikreins- Kallikreins
- Kalliginogenase
- Kallikrein
- Kininogenase
- Callicrein
- Kallidinogenase
- Kinin-Forming Enzyme
- Enzyme, Kinin-Forming
- Kinin Forming Enzyme
|
Below are MeSH descriptors whose meaning is more general than "Kallikreins".
Below are MeSH descriptors whose meaning is more specific than "Kallikreins".
This graph shows the total number of publications written about "Kallikreins" by people in this website by year, and whether "Kallikreins" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 1 | 2 |
| 2001 | 1 | 0 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 2 | 1 | 3 |
| 2004 | 1 | 2 | 3 |
| 2005 | 2 | 2 | 4 |
| 2006 | 1 | 4 | 5 |
| 2007 | 2 | 0 | 2 |
| 2008 | 3 | 1 | 4 |
| 2009 | 1 | 1 | 2 |
| 2010 | 2 | 3 | 5 |
| 2011 | 5 | 8 | 13 |
| 2012 | 5 | 2 | 7 |
| 2013 | 3 | 4 | 7 |
| 2014 | 4 | 2 | 6 |
| 2015 | 4 | 9 | 13 |
| 2016 | 10 | 9 | 19 |
| 2017 | 6 | 10 | 16 |
| 2018 | 11 | 6 | 17 |
| 2019 | 1 | 10 | 11 |
| 2020 | 10 | 12 | 22 |
| 2021 | 4 | 6 | 10 |
| 2023 | 1 | 0 | 1 |
| 2024 | 1 | 1 | 2 |
Below are the most recent publications written about "Kallikreins" by people in Profiles.
-
A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer. Nat Commun. 2024 Nov 06; 15(1):9587.
-
CRISPR-Based Therapy for Hereditary Angioedema. N Engl J Med. 2025 Jan 30; 392(5):458-467.
-
Serendipitous Discovery of T Cell-Produced KLK1b22 as a Regulator of Systemic Metabolism. Immunohorizons. 2023 06 01; 7(6):493-507.
-
COVID-19 and hereditary angioedema: Incidence, outcomes, and mechanistic implications. Allergy Asthma Proc. 2021 Nov 01; 42(6):506-514.
-
Prostate Cancer Screening and Incidence among Aging Persons Living with HIV. J Urol. 2022 02; 207(2):324-332.
-
A phase II study of docetaxel plus lycopene in metastatic castrate resistant prostate cancer. Biomed Pharmacother. 2021 Nov; 143:112226.
-
Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort. J Urol. 2021 11; 206(5):1147-1156.
-
Individual Patient Data Meta-analysis of Discrimination of the Four Kallikrein Panel Associated With the Inclusion of Prostate Volume. Urology. 2021 11; 157:102-106.
-
Salvage therapy for prostate cancer after radical prostatectomy. Nat Rev Urol. 2021 11; 18(11):643-668.
-
KLK3 SNP-SNP interactions for prediction of prostate cancer aggressiveness. Sci Rep. 2021 04 29; 11(1):9264.